Frank P. B. Dubois

Frank P. B. Dubois

Auto-generated profile, based on publicly available information

Frank P. B. Dubois

Institute of Pathology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 November 2020 in Cell
Verified
Journal Article
Closed access
CCCarol C.L. Chen
Carol C.L. Chen
SDShriya Deshmukh
Shriya Deshmukh
SJSelin Jessa
Selin Jessa
DHDjihad Hadjadj
Djihad Hadjadj
VLVéronique Lisi
Véronique Lisi
NJNada Jabado
Nada Jabado

28 June 2022 in Nature Reviews Cancer
Verified
Journal Article
Closed access
PDF file
FDFrank Dubois
Frank Dubois
NSNikos Sidiropoulos
Nikos Sidiropoulos
JWJoachim Weischenfeldt
Joachim Weischenfeldt
RBRameen Beroukhim
Rameen Beroukhim

4 July 2022 in Nature Cancer
Verified
Journal Article
Closed access
PDF file
FDFrank P. B. Dubois
Frank P. B. Dubois
OSOfer Shapira
Ofer Shapira
NGNoah F. Greenwald
Noah F. Greenwald
TZTravis Zack
Travis Zack
JWJeremiah Wala
Jeremiah Wala
PBPratiti Bandopadhayay
Pratiti Bandopadhayay

8 July 2022 in Cancer Research
Verified
Journal Article
Open access
PDF file
JTJessica W. Tsai
Jessica W. Tsai
PCPaloma Cejas
Paloma Cejas
DWDayle K. Wang
Dayle K. Wang
SPSmruti Patel
Smruti Patel
DWDavid W. Wu
David W. Wu
TPTimothy N. Phoenix
Timothy N. Phoenix
Forkhead box R2 (FOXR2) is a forkhead transcription factor located on the X chromosome whose expression is normally restricted to the testis. In this study, we performed a pan-cancer analysis of FOXR2 activation across more than 10,000 adult and pediatric cancer samples and found FOXR2 to be aberrantly upregulated in 70% of all cancer types and 8% of all individual tumors. The majority of tumors (78%) aberrantly expressed FOXR2 through a previously undescribed epigenetic mechanism that involves hypomethylation of a novel promoter, which was functionally validated as necessary for FOXR2 expression and proliferation in FOXR2-expressing cancer cells. FOXR2 promoted tumor growth across multiple cancer lineages and co-opted ETS family transcription circuits across cancers. Taken together, this study identifies FOXR2 as a potent and ubiquitous oncogene that is epigenetically activated across the majority of human cancers. The identification of hijacking of ETS transcription circuits by FOXR2 extends the mechanisms known to active ETS transcription factors and highlights how transcription factor families cooperate to enhance tumorigenesis. Significance: This work identifies a novel promoter that drives aberrant FOXR2 expression and delineates FOXR2 as a pan-cancer oncogene that specifically activates ETS transcriptional circuits across human cancers. See related commentary by Liu and Northcott, p. 2977

7 August 2025 in Cancer Discovery
Verified
Journal Article
Closed access
GMGiulia Montuori
Giulia Montuori
FTFengyu Tu
Fengyu Tu
DQDi Qin
Di Qin
RSRachel Schmargon
Rachel Schmargon
ERElias Rodriguez-Fos
Elias Rodriguez-Fos
JDJan R. Dörr
Jan R. Dörr
Extrachromosomal DNA (ecDNA) amplification enhances intercellular oncogene dosage variability and accelerates tumor evolution by violating foundational principles of genetic inheritance through its asymmetric mitotic segregation. Spotlighting high-risk neuroblastoma, we demonstrate how ecDNA amplification undermines the clinical efficacy of current therapies in cancers with extrachromosomal MYCN amplification. Integrating theoretical models of oncogene copy number–dependent fitness with single-cell ecDNA quantification and phenotype analyses, we reveal that ecDNA copy-number heterogeneity drives phenotypic diversity and determines treatment sensitivity through mechanisms unattainable by chromosomal oncogene amplification. We demonstrate that ecDNA copy number directly influences cell fate decisions in cancer cell lines, patient-derived xenografts, and primary neuroblastomas, illustrating how extrachromosomal oncogene dosage–driven phenotypic diversity offers a strong evolutionary advantage under therapeutic pressure. Furthermore, we identify senescent cells with reduced ecDNA copy numbers as a source of treatment resistance in neuroblastomas and outline a strategy for their targeted elimination to improve the treatment of MYCN-amplified cancers. Significance: ecDNA-driven tumor genome evolution provides a major challenge to curative cancer therapies. We demonstrate that ecDNA copy-number dynamics drives treatment resistance by promoting oncogene dosage–dependent phenotypic heterogeneity in MYCN-amplified cancers. Exploiting phenotype-specific vulnerabilities of ecDNA cells, therefore, presents a powerful strategy to overcome treatment resistance. See related commentary by Korsah, p. 1979

7 May 2020 in American Journal of Neuroradiology
Verified
Journal Article
Closed access
PDF file
CJCamilo E. Jaimes
Camilo E. Jaimes
SVS. Vajapeyam
S. Vajapeyam
DBD. Brown
D. Brown
PKP.-C. Kao
P.-C. Kao
CMC. Ma
C. Ma
TPTina Young Poussaint
Tina Young Poussaint
BACKGROUND AND PURPOSE: Recent advances in molecular techniques have characterized distinct subtypes of diffuse intrinsic pontine gliomas. Our aim was the identification of MR imaging correlates of these subtypes. MATERIALS AND METHODS: Initial MRIs from subjects with diffuse intrinsic pontine gliomas recruited for a prospective clinical trial before treatment were analyzed. Retrospective imaging analyses included FLAIR/T2 tumor volume, tumor volume enhancing, the presence of cyst and/or necrosis, median, mean, mode, skewness, kurtosis of ADC tumor volume based on FLAIR, and enhancement at baseline. Molecular subgroups based on EGFR and MGMT mutations were established. Histone mutations were also determined (H3F3A, HIST1H3B, HIST1H3C). Univariate Cox proportional hazards regression was used to test the association of imaging predictors with overall and progression-free survival. Wilcoxon rank sum, Kruskal-Wallis, and Fisher exact tests were used to compare imaging measures among groups. RESULTS: Fifty patients had biopsy and MR imaging. The median age at trial registration was 6 years (range, 3.3–17.5 years); 52% were female. On the basis of immunohistochemical results, 48 patients were assigned to 1 of 4 subgroups: 28 in MGMT–/epidermal growth factor receptor (EGFR)–, 14 in MGMT–/EGFR+, 3 in MGMT+/EGFR–, and 3 in MGMT+/EGFR+. Twenty-three patients had histone mutations in H3F3A, 8 in HIST1H3B, and 3 in HIST1H3C. Enhancing tumor volume was near-significantly different across molecular subgroups (P = .04), after accounting for the false discovery rate. Tumor volume enhancing, median, mode, skewness, and kurtosis ADC T2-FLAIR/T2 were significantly different (P ≤ .048) between patients with H3F3A and HIST1H3B/C mutations. CONCLUSIONS: MR imaging features including enhancement and ADC histogram parameters are correlated with molecular subgroups and mutations in children with diffuse intrinsic pontine gliomas.